Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Doximity, Inc.NYSE: DOCS
Accounts Payables · Q2 FY2027 · quarter ended Sep 2026
Accounts payables turns positive
Q2 FY2027 accounts payables was $4.7M, compared with -$2.17M a year earlier. Trailing-twelve-month accounts payables was $8.87M.
Context
- Accounts payables amounted to 0.7% of revenue in FY2026, up 0.5 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $4.7M or moves back toward the trailing-twelve-month quarterly average of $2.22M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2026
- 4.27M USD
- Year-over-year change
- +743.7%
- 4-year CAGR
- -16.2%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 4.27M | +743.7% |
| FY2025 | 2025-03-31 | (663K) | -108.0% |
| FY2024 | 2024-03-31 | 8.33M | +4372.8% |
| FY2023 | 2023-03-31 | (195K) | -102.3% |
| FY2022 | 2022-03-31 | 8.66M | — |
Accounts Payables vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 accounts payables of $8.87M is the 6th largest of the 10 companies compared; the peer median is $200K.
- Its year-over-year change of +247.8% is the 2nd highest of 7, against a peer median of +115.6%.
- Accounts payables amounts to 1.3% of revenue for DOCS, versus a peer median of 0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $107M | -31.8% | +60.8% | 1.3% | |
| LTM Sep 2026 | $41.71M | — | — | 3.3% | |
| LTM Jun 2026 | $33.2M | +115.8% | — | 0.2% | |
| LTM Jul 2026 | $14M | -6266.1% | — | 0.5% | |
| LTM Sep 2026 | $11.29M | +164.1% | -2.9% | 0.7% | |
| LTM Sep 2026 | $8.87M | +247.8% | — | 1.3% | |
| LTM Jul 2026 | $8.1M | +274.4% | — | 0.6% | |
| LTM Jun 2026 | $200K | +115.4% | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jul 2026 | $0 | — | -45.7% | 0.0% | |
| Peer median (excluding DOCS) | $200K | +115.6% | -2.9% | 0.5% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| Deferred Income Tax | (41.25M) | 13.23M | (8.59M) | (11.59M) | 32.14M |
| Stock-Based Compensation | 31.44M | 47.83M | 51.08M | 72.39M | 121.63M |
| Change in Working Capital | (40.33M) | (21.03M) | (24.52M) | (24.1M) | (45.7M) |
| Accounts Receivables | (31.02M) | (26.24M) | 3.99M | (27.21M) | (16.88M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.66M | (195K) | 8.33M | (663K) | 4.27M |
| Other Working Capital | (17.98M) | 5.4M | (36.85M) | 3.77M | (33.09M) |
| Other Non-Cash Items | 16.89M | 16.47M | 8.29M | 2.72M | 7.96M |
| Operating Cash Flow | 126.58M | 179.6M | 184.1M | 273.27M | 326.46M |
| Capital Expenditures | (5.7M) | (6.18M) | (5.8M) | (6.53M) | (8.96M) |
| Acquisitions (Net) | 0 | (53.5M) | 0 | 0 | (26.53M) |
| Purchases of Investments | (1.32B) | (190.56M) | (472.87M) | (675.56M) | (389.16M) |
| Sales of Investments | 681.72M | 190.32M | 509.85M | 652.78M | 571.82M |
| Other Investing Activities | 595K | 0 | (5.65M) | 0 | 0 |
| Investing Cash Flow | (640.57M) | (59.92M) | 31.19M | (29.3M) | 147.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 553.91M | 0 | 0 | 23.3M | 13.68M |
| Common Stock Repurchased | (2.7M) | (85.32M) | (280.72M) | (120.29M) | (431.65M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.21M | 10.86M | 4.19M | (34.15M) | (46.09M) |
| Financing Cash Flow | 560.42M | (74.46M) | (276.52M) | (131.14M) | (464.06M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 46.42M | 45.22M | (61.24M) | 112.83M | 9.56M |
| Free Cash Flow | 120.88M | 173.42M | 178.3M | 266.74M | 317.5M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.